United States: 美国安进公司新起诉以寻求关于美国生物性产品价格竞争与创新法案


In the most recent lawsuit involving the Biologics Price Competition and Innovation Act ("BPCIA"), Amgen filed a complaint on March 4, 2016, seeking a declaration that Sandoz has failed to participate in the BPCIA's information-exchange provisions and an order compelling Sandoz to do so. Notably, the complaint does not include a claim for patent infringement based on Sandoz's application for FDA approval to market a biosimilar version of the drug product Neulasta?. Rather, the complaint is self-described as "an action to enforce the patent-dispute-resolution provisions of the BPCIA." This is a departure from Amgen's February 26, 2016 complaint against Sandoz (concerning the immunosuppressant Enbrel?), in which Amgen alleged similar behavior by Sandoz but brought only claims for patent infringement.

The BPCIA established a unique and elaborate process for information exchange between the biosimilar applicant and the reference product sponsor ("RPS") to resolve patent disputes. The Federal Circuit summarized the process, which has become known as the "patent dance," as follows:

Under that process, codified at 42 U.S.C. § 262(l), the biosimilar applicant grants the RPS confidential access to its aBLA [abbreviated Biologics License Application] and the manufacturing information regarding the biosimilar product no later than 20 days after the FDA accepts its application for review. Id. § 262(l)(1)-(2). The parties then exchange lists of patents for which they believe a claim of patent infringement could reasonably be asserted by the RPS, as well as their respective positions on infringement, validity, and enforceability of those patents. Id. § 262(l)(3). Following that exchange, which could take up to six months, the parties negotiate to formulate a list of patents ("listed patents") that would be the subject of an immediate infringement action, id. § 262(l)(4)-(5), and the RPS then sues the biosimilar applicant within 30 days, id. § 262(l)(6). That information exchange and negotiation thus contemplates an immediate infringement action brought by the RPS based only on listed patents.

Amgen Inc. v. Sandoz Inc.. In Amgen, the Federal Circuit held that a biosimilar applicant (Sandoz in that case as well) did not violate the BPCIA by failing to disclose its application and manufacturing information as set forth in § 262(l)(1)-(2).

The newly filed Amgen complaint raises two related but separate issues: (i) whether a biosimilar applicant must participate in the patent selection procedures set forth in § 262(l)(4)-(5) after providing the RPS with its application and manufacturing information, as well as its contentions as to invalidity, unenforceability, and noninfringement, and (ii) whether an applicant's decision not to participate compels the RPS to file a patent infringement lawsuit under § 262(l)(6) prior to the negotiation and exchange of patent lists as set forth under § 262(l)(4) and, if necessary, § 262(l)(5).

Specifically, Amgen has alleged that Sandoz filed an aBLA with the FDA "in order to obtain approval to commercially manufacture, use, offer to sell, and sell, and import into the United States the Sandoz Pegfilgrastim Product, a biosimilar version of Plaintiffs' NEULASTA? (pegfilgrastim) product." According to Amgen, "NEULASTA? is indicated to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs."

As it did in its Enbrel? complaint, Amgen asserts that Sandoz engaged in the initial stages of the "patent dance" by providing Amgen access to documents Sandoz "represented to constitute its aBLA and information relating to the manufacturing process for the Sandoz Pegfilgrastim Product." In response, and pursuant to § 262(l)(3)(A), Amgen provided Sandoz with a list of two patents (U.S. Patent Nos. 8,940,878 and 5,824,784) "for which it believed a claim of patent infringement could reasonably be asserted against the Sandoz Pegfilgrastim Product." In response, Sandoz provided "contentions that the '878 and '784 patents are invalid, unenforceable, or will not be infringed by the commercial marketing of the biological product that is the subject of the Sandoz aBLA."

Sandoz, however, "also stated that it no longer wished to follow the strictures of the BPCIA because it effectively had Plaintiffs' positions pursuant to 42 U.S.C. § 262(l)(3)(C)" and that it "was 'waiving' its right to receive Plaintiffs' statement pursuant to 42 U.S.C. § 262(l)(3)(C), and declared that negotiations pursuant to 42 U.S.C. § 262(l)(4) and (5) [regarding the identity of patents that would be subject to a patent infringement suit] were unnecessary." Amgen further alleges that Sandoz "then insisted that Plaintiffs file an action for patent infringement pursuant to 42 U.S.C. § 262(l)(6) within 30 days, i.e., by March 4, 2016," and if Plaintiffs did not do so, then "the penalty for an untimely suit—that the 'sole and exclusive remedy' for any infringement be limited to a 'reasonable royalty'—applies."

Accordingly, Amgen is seeking a declaration that Sandoz is required to comply with § 262(l)(4) and (5), that Sandoz's failure to comply with those provisions "means there can be no 'immediate patent infringement action' under 42 U.S.C. § 262(l)(6)," and that Amgen's "not filing a patent infringement action by March 4, 2016" does not deprive it "of the remedies for infringement available under 35 U.S.C. § 271(e)(4), including lost profits damages and injunctive relief." Amgen did not assert an alternative claim for patent infringement.  

This case highlights yet another dispute between an RPS and a biosimilar applicant as they navigate through the uncharted waters of the BPCIA's patent dance. In attempting to forego Amgen's contentions regarding infringement, validity, and enforceability under § 262(l)(3) and the subsequent negotiation over the list of patents to be litigated, Sandoz is attempting to accelerate the time by which Amgen must file a patent infringement action by as much as 80 days or more, which is significant given reports that Neulasta? generates more than $4 billion in annual revenues.

The current district court case is pending in the Newark division in the District of New Jersey (Civil Action No. 16-cv-01276) and has been assigned to Judge Stanley R. Chesler and Magistrate Judge Cathy L. Waldor. Judge Chesler is one of the designated Patent Pilot Program judges in the District of New Jersey. Congress established the Patent Pilot Program in 2011 to "encourage enhancement of expertise" in patent cases among district judges. The program directs patent cases to specific judges who volunteer to become "pilot judges."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions